NEW YORK--(BUSINESS WIRE)--Phosplatin Therapeutics (“Phosplatin”) today announced it has granted a regional license for its platinum agent, PT-112, to a U.S. based pharmaceutical company with extensive operations in China (“the partner”) for development and commercialization in China and certain adjacent territories. The agreement grants the partner the rights to develop and market PT-112 in Greater China for use in the treatment of oncology indications.
PT-112 is a novel molecule, a member of the phosphaplatin family of compounds, currently undergoing Phase 1 clinical development in the U.S. as an anticancer agent in solid tumors. When compared to prior members of the platinum therapeutic class, PT-112’s unique electrochemistry and plasma stability engendered improved tolerability and safety, and in pre-clinical models proved highly efficacious, including in treatment resistant cell lines and patient-derived tumor models.
Help employers find you! Check out all the jobs and post your resume.
PT-112 is a novel molecule, a member of the phosphaplatin family of compounds, currently undergoing Phase 1 clinical development in the U.S. as an anticancer agent in solid tumors. When compared to prior members of the platinum therapeutic class, PT-112’s unique electrochemistry and plasma stability engendered improved tolerability and safety, and in pre-clinical models proved highly efficacious, including in treatment resistant cell lines and patient-derived tumor models.
Help employers find you! Check out all the jobs and post your resume.
